Efficacy and safety of treatment simplification to atazanavir/ritonavir1lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 6, 2014, Pages 1843-1849

  Mondi, A ^a   Fabbiani, M ^a   Ciccarelli, N ^a   Colafigli, M ^a   D'Avino, A ^a   Borghetti, A ^a   Gagliardini, R ^a   Cauda, R ^a   De Luca, A ^b   Di Giambenedetto, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Antiviral; Combined antiretroviral therapy; Dual therapy

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; CALCIUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; PARATHYROID HORMONE; TRIACYLGLYCEROL; VITAMIN D; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; RITONAVIR;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY COLIC; KIDNEY FUNCTION; LUMBAR SPINE; MALE; OPEN STUDY; OSTEOPOROSIS; PILOT STUDY; SPINE FRACTURE; TRUNK; UROLITHIASIS; VIRUS LOAD; VITAMIN SUPPLEMENTATION; ADVERSE EFFECTS; AGED; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATAZANAVIR SULFATE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PILOT PROJECTS; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84930517019     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv037     Document Type: Article

References (40)

1. Arribas JR, Delgado R, Arranz A et al. OK04 Study Group. Lopinavirritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51: 147-52.
2. Arribas JR, Clumeck N, Nelson M et al. The MONET trial:week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r)monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load ,50 HIV-1 RNA copies/mL at baseline. HIV Med 2012; 13: 398-405.
3. Katlama C, Valantin MA, Algarte-Genin M et al. Efficacy of darunavir/ ritonavir maintenance monotherapy in patients with HIV-1 viral suppression:a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24: 2365-74.
4. Reynes J, Lawal A, Pulido F et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects:the progress study, 48-week results. HIV Clin Trials 2011; 12: 255-67.
5. Di Giambenedetto S, Fabbiani M, Colafigli M et al. Safety and feasibility of treatment simplification to atazanavir/ritonavir+lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors+atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother 2013; 68: 1364-72.
6. Antinori A, Arendt G, Becker JT et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 1789-99.
7. Serrano-Villar S, Sainz T, Lee SA et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10: e1004078.
8. Castagna A, Spagnuolo V, Galli L et al. MODAt Study Group. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results. AIDS2014; 28:2269-79.
9. Cahn P, Andrade-Villanueva J, Arribas JR et al. on behalf of the GARDEL Study Group. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 2014; 14: 572-80.
10. Ofotokun I, Sheth AN, Sanford et al. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study. AIDS Res Hum Retroviruses 2012; 28: 1196-206.
11. Gatell JM, Arribas JR, Girard PM et al. Non-inferiority of dual-therapy (DT) with lopinavir/ritonavir (LPV/r) plus lamivudine (3TC) vs triple-therapy (TT) with LPV/r plus two nucleos(t)ides (NRTIs) for maintenance of HIV-1 viral suppression: 48-week results of the OLE study. In: Abstracts of the Twentieth International AIDS Conference, Melbourne, Australia, 2014. Abstract LBPE17. International AIDS Society, Geneva, Switzerland.
12. Stellbrink HJ, Pulik P, Szlavik J et al. Maraviroc (MVC) once daily with darunavir/ ritonavir (DRV/r) in a 2-drug regimen compared to emtricitabine/ tenofovir (TDF/FTC) with DRV/r: 48-week results from MODERN (Study A4001095). In: Abstracts of the Twentieth International AIDS Conference, Melbourne, Australia, 2014. Abstract TUAB0101. International AIDS Society, Geneva, Switzerland.
13. Van Lunzen J, Pozniak A, Gatell J et al. HARNESS study: ritonavirboosted atazanavir (ATV/r)+raltegravir (RAL) switch study in virologically suppressed, HIV-1-infected patients. In: Abstracts of the Twentieth International AIDS Conference, Melbourne, Australia, 2014. Abstract LBPE19. International AIDS Society, Geneva, Switzerland.
14. Raffi F, Babiker AG, Richert L et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet 2014; 384: 1942-51.
15. Rockwood N, Mandalia S, Bower M et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS 2011; 25: 1671-3.
16. Hamada Y, Nishijima T, Watanabe K et al. High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy. Clin Infect Dis 2012; 55: 1262-9.
17. Fabbiani M, Bracciale L, Doino M et al. Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. J Infect 2011; 62: 319-21.
18. Perez-Molina JA, Rubio R, Rivero A et al. Switching to dual therapy (atazanavir/ ritonavir+ lamivudine) vs. standard triple therapy (atazanavir/ ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study). In:Abstracts of the Twentieth International AIDS Conference, Melbourne, Australia, 2014. Abstract LBPE18. International AIDS Society, Geneva, Switzerland.
19. Fabbiani M, Di Giambenedetto S, Quiros-Roldan E et al. Simplification to atazanavir/ritonavir +lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. J Int AIDS Soc2014; 17 Suppl 3: 19808.
20. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-9.
21. McDonald C, Uy J, Hu Wet al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 2012; 2: 259-64.
22. Landovitz RL, Ribaudo HJ, Ofotokun I et al. Efficacy and tolerability of atazanavir, raltegravir, or darunavir with FTC/tenofovir: ACTG 5257. In:Abstracts of the Twenty-first Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2014. Abstract 85. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
23. Farr AM, Johnston SS, Ritchings C et al. No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting. J Int AIDS Soc 2014; 17 Suppl 3: 19538.
24. Fabbiani M, Bracciale L, Doino M et al. Lipid-lowering effect of tenofovir in HIV-infected patients. J Antimicrob Chemother 2011; 66: 682-3.
25. Scherzer R, Estrella M, Li Y et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS 2012; 26: 867-75.
26. Stellbrink HJ, Orkin C, Arribas JR et al. ASSERT Study Group. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010; 51: 963-72.
27. McComsey GA, Kitch D, Daar ES et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavirlamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 2011; 203: 1791-801.
28. Havens PL, Stephensen CB, Hazra R et al. Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions 063 study team. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis 2012; 54: 1013-25.
29. Dao CN, Patel P, Overton ET et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52: 396-405.
30. Arribas J, Bernardino J, Hill A et al. Effects of switching to PI monotherapy on measures of lipoatrophy: meta-analysis of six randomized HIV clinical trials. In: Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 2014. Abstract P287.
31. Valantin MA, Kolta S, Flandre P et al. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy. HIV Med 2012; 13: 505-15.
32. Erlandson KM, Kitch D, Tierney C et al. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS 2013; 27: 2069-79.
33. Shikuma CM, Zackin R, Sattler F et al. AIDS Clinical Trial Group 892 Team. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 1223-30.
34. McDermott AY, Terrin N,Wanke C et al. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 2005; 41: 1662-70.
35. Martin A, Bloch M, Amin J et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49: 1591-601.
36. Vernazza P, Daneel S, Schiffer V et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007; 21: 1309-15.
37. Pérez-Valero I, González-Baeza A, Estébanez M et al. A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals. Clin Infect Dis 2014; 59: 1627-34.
38. Paton N, Stohr W, Arenas-Pinto A et al. PIVOT Trial Group. Randomised controlled trial of a PI monotherapy switch strategy for long-term HIV management. In: Abstracts of the Twenty-first Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2014. Abstract 550LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
39. Valero-Perez I, Pasquau J, Rubio R et al. CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study. J Int AIDS Soc 2014; 17 Suppl 3: 196564.
40. Clarke A, Johanssen V, Gerstoft J et al. Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues. J Int AIDS Soc 2014; 17 Suppl 3: 19526.